Physician profile
Eric Bowman
NPI 1053571315
$14,887.98
in general payments reported to CMS, 2019-2025
47 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,135 · 2020: $1,554 · 2021: $2,383 · 2022: $2,331 · 2023: $1,967 · 2024: $2,400 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,465 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,464.73 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,989.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,507.16 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,385.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,166.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $968.70 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Astrazeneca Pharmaceuticals Lp | $823.69 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $704.31 | 2019-2025 | Jardiance |
| Pfizer INC. | $673.87 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $444.76 | 2019-2025 | Xifaxan |
| Bone Support INC. | $435.24 | 2024-2025 | Ceramentbone Void Filler, Cerament G |
| Abbott Laboratories | $338.52 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $296.90 | 2022-2025 | |
| Amarin Pharma, INC. | $295.28 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $287.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $281.71 | 2019-2023 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $272.13 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Sanara Medtech INC. | $248.47 | 2022 | |
| Xeris Pharmaceuticals, INC. | $242.51 | 2021-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $239.34 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Phathom Pharmaceuticals, INC. | $202.10 | 2024-2025 | Voquezna |
| Allergan, INC. | $192.11 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.35 | 2024-2025 | Caplyta |
| Amgen INC. | $170.91 | 2019-2024 | Otezla, Repatha, Evenity |
| Sumitomo Pharma America, INC. | $165.19 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $148.87 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $140.80 | 2021-2025 | Nexletol |
| Depuy Synthes Sales INC. | $136.71 | 2021 | |
| Idorsia Pharmaceuticals US INC | $98.54 | 2022-2023 | Quviviq |
| Microport Orthopedics INC | $94.47 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $90.33 | 2019-2022 | |
| Lundbeck LLC | $79.09 | 2019-2023 | Vyepti |
| Grifols USA, LLC | $67.09 | 2019-2023 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $62.39 | 2021-2022 | |
| Eisai INC. | $60.09 | 2019-2021 | |
| Verona Pharma, INC. | $54.19 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $52.63 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $50.29 | 2019-2023 | |
| Radius Health, INC. | $43.58 | 2020 | |
| Axsome Therapeutics, INC. | $38.72 | 2025 | Auvelity |
| Astellas Pharma US INC | $37.56 | 2019 | |
| Horizon Therapeutics Plc | $24.92 | 2021 | |
| Kyowa Kirin, INC. | $22.09 | 2025 | |
| Sanofi Pasteur INC. | $17.04 | 2023 | |
| Nalpropion Pharmaceuticals LLC | $17.02 | 2019 | |
| Insulet Corporation | $14.46 | 2024 | Omnipod |
| Exact Sciences Corporation | $14.39 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.